Development of the polymer micelle carrier system for doxorubicin

J Control Release. 2001 Jul 6;74(1-3):295-302. doi: 10.1016/s0168-3659(01)00341-8.

Abstract

We show the result of pre-clinical study of NK911, a polymeric micelle carrier system for doxorubicin (DOX). The NK911 micelle carrier consists of polyethyleneglycol and conjugated doxorubicin-polyaspartic acid. It has high hydrophobic inner core, and therefore can entrap the sufficient amount of DOX. NK911 has a small particle size of about 40 nm in diameter that accumulates in tumor tissue by EPR effect showing much stronger activity than the free DOX. We plan to perform a clinical trial at National Cancer Center Hospital, Japan from 2001.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Antibiotics, Antineoplastic / pharmacology
  • Chemical Phenomena
  • Chemistry, Physical
  • Doxorubicin / administration & dosage*
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Drug Carriers
  • Drug Stability
  • Humans
  • Mice
  • Micelles
  • Neoplasm Transplantation
  • Neoplasms, Experimental / drug therapy
  • Particle Size
  • Peptides / administration & dosage*
  • Peptides / pharmacokinetics
  • Peptides / pharmacology
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / pharmacokinetics
  • Polyethylene Glycols / pharmacology
  • Polymers
  • Tumor Cells, Cultured

Substances

  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Micelles
  • NK911
  • Peptides
  • Polymers
  • Polyethylene Glycols
  • Doxorubicin